Supernus announces FDA approval of sNDA for Oxtellar XR

Supernus Pharmaceuticals announced that the United States FDA has approved the company’s supplemental new drug application for Oxtellar XR. The application requested FDA approval to expand the indication for Oxtellar XR beyond the current indication of adjunctive therapy in the treatment of partial-onset seizures in adults and in children 6 to 17 years of age.
https://thefly.com/landingPageNews.php?id=2837565